Revanesse Versa; Revanesse Versa+ (with lidocaine); Revanesse Lips+ (with lidocaine)
Prollenium Medical Technologies, Inc. · Decision date Dec 22, 2025
What did the FDA decide?
FDA records P160042/S029 as a supplement to PMA P160042, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 22, 2025.
FDA approval order statement
approval for modifications to cleanroom layout in a secondary manufacturing facility
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Dec 22, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P160042/S029
- Regulatory pathway
- PMA supplement
- Product code
- LMH
- Decision code
- OK30
- Decision date
- Dec 22, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
- Product code
- LMH
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P160042. Subsequent supplements may change the device or its indications.
FDA decision timeline
P160042 · Original PMA
REVANESSE ULTRA
P160042/S029 received
Application receipt date recorded by FDA.
P160042/S029 · FDA decision
30-Day Notice
P160042/S031 · Related supplement
Revanesse Versa / Revanesse Versa+ (with lidocaine) / Revanesse Lips+ (with lidocaine)
P160042/S032 · Related supplement
Revanesse Versa, Revanesse Versa+ (with lidocaine) and Revanesse Lips+ (with lidocaine)
Timeline entries are records held by MedtechLedger for P160042. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160042
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
REVANESSE ULTRAP160042 | Prollenium Medical Technologies, Inc. | PMA approval | Aug 4, 2017 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | May 8, 2026 | FDA | |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
saypha ChiQP250021/S001 | Croma-Pharma GmbH | PMA supplement | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Prollenium Medical Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 138 Industrial Pkwy. N., Aurora, L4G 4C3
Sources and methodology
- Original FDA record: P160042/S029
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



